Previous research has suggested that breast cancer treatments that take place between diagnosis and surgery can help improve surgical success and breast cancer outcomes. Therefore, the development of breast cancer treatments that can slow breast cancer growth during this time is an important area of research.
A recent research study explored the potential benefits of treating breast cancer patients with lapatinib, a HER2-specific breast cancer treatment. For this study, 60 breast cancer patients were treated with lapatinib for the 3 weeks between breast biopsy and surgery. Breast tissue samples after surgery were examined for differences in breast cancer growth compared to women treated with a placebo. The study investigators reported:
- Cell growth decreased by about 9% in patients treated with lapatinib, while cell growth increased by 15% in placebo-treated patients.
- The decrease in breast cancer cell growth was greater in estrogen receptor-negative tumors (35% decrease) than in estrogen receptor-positive tumors (12% decrease).
- Breast tumor size was smaller after lapatinib treatment (18 mm) than after placebo treatment (24 mm).
- Breast cancer tumor progression was only 27% on lapatinib compared to 56% growth on placebo treatment.
- Lapatinib treatment resulted in a 14% partial response, while placebo treatment was associated with only a 4% partial response.
To learn about diet and lifestyle choices to reduce your breast cancer risk, read my FREE book FIGHT NOW: EAT & LIVE PROACTIVELY AGAINST BREAST CANCER. Please recommend to anyone interested in breast cancer, breast cancer treatment, and breast cancer symptoms.